ASCO Conference Coverage
Featured Articles
(Merck) May 23, 2018 - Merck, known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-407 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with carboplatin-paclitaxel or nab-paclitaxel, as first-line treatment for metastatic squamous non-small cell lung cancer (sNSCLC),...
Read Article
(NPR/Shots Blog) May 16, 2018 - Sometimes less may be better when it comes to treatment for breast cancer. A new study finds that women who have been diagnosed with early-stage HER2-positive breast cancer did just as well with six months of treatment with the drug Herceptin (trastuzumab) as did women who received a 12-month course of...
Read Article
Latest Articles
May 17, 2018
May 17, 2018
May 17, 2018
May 17, 2018
May 17, 2018
May 17, 2018
May 17, 2018
May 17, 2018
View More
News Commentary
Editor Image
05 Jun, 2017 | by Howard S. Hochster, MD
The combined analysis of more than 12000 patients in 6 randomize trial was...
View Comment
Editor Image
05 Jun, 2017 | by Howard S. Hochster, MD
It's not the reporting but early intervention by caregivers to deal with...
View Comment
View More
OBR Blog
With about two weeks to go until the 2018 ASCO Annual Meeting, a pre-meeting press cast featured abstracts of interest... Read more
May 16, 2018
By Jay Grisolano, PhD and Stephanie Ritz, PhD Approximately a quarter of breast cancer patients are classified as... Read more
June 05, 2017